Edgar Filing: BALTIMORE DAVID

Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

BALTIMORE DAVID

2. Issuer Name and Ticker or Trading Symbol
Regulus Therapeutics Inc. [RGLS]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	_____ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2018

(Street)

SAN DIEGO, CA 92121

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2018		A		40,339	A	⁽¹⁾	44,131 ⁽²⁾	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option (Right to Buy)

$ 4.56

11/12/2018

10,625 ⁽²⁾

⁽³⁾

01/01/2019

Common Stock

10,625 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 4.56

11/12/2018

1,875 ⁽²⁾

⁽³⁾

01/01/2019

Common Stock

1,875 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 4.56

11/12/2018

625 ⁽²⁾

⁽³⁾

12/01/2019

Common Stock

625 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 4.56

11/12/2018

1,458 ⁽²⁾

⁽³⁾

12/01/2019

Common Stock

1,458 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 20.88

11/12/2018

625 ⁽²⁾

⁽³⁾

01/02/2021

Common Stock

625 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 20.88

11/12/2018

1,458 ⁽²⁾

⁽³⁾

01/02/2021

Common Stock

1,458 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 31.92

11/12/2018

625 ⁽²⁾

⁽³⁾

02/08/2022

Common Stock

625 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 31.92

11/12/2018

1,458 ⁽²⁾

⁽³⁾

02/08/2022

Common Stock

1,458 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 111.84

11/12/2018

416 ⁽²⁾

⁽³⁾

06/09/2023

Common Stock

416 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 111.84

11/12/2018

1,458 ⁽²⁾

⁽³⁾

06/09/2023

Common Stock

1,458 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 74.64

11/12/2018

1,458 ⁽²⁾

⁽³⁾

05/21/2024

Common Stock

1,458 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 74.64

11/12/2018

416 ⁽²⁾

⁽³⁾

05/21/2024

Common Stock

416 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 120.24

11/12/2018

1,458 ⁽²⁾

⁽³⁾

06/08/2025

Common Stock

1,458 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 74.4

11/12/2018

3,051 ⁽²⁾

⁽³⁾

05/31/2026

Common Stock

3,051 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 17.4

11/12/2018

2,500 ⁽²⁾

⁽³⁾

05/30/2027

Common Stock

2,500 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 8.52

11/12/2018

6,250 ⁽²⁾

⁽⁵⁾

05/15/2028

Common Stock

6,250 ⁽²⁾

⁽⁴⁾

Stock Option (Right to Buy)

$ 8.76

11/12/2018

4,583 ⁽²⁾

⁽⁶⁾

05/31/2028

Common Stock

4,583 ⁽²⁾

⁽⁴⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
BALTIMORE DAVID C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121	X

Signatures

Christopher Aker, Attorney in Fact		11/13/2018
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I. The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date.
(2)	Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018.
(3)	The shares subject to the cancelled option were fully vested.
(4)	On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the listed option. In exchange for the options cancelled, the reporting person received Restricted Stock Units as reported above in Table I.
(5)	The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant.
(6)	The cancelled option provided for vesting in twelve equally monthly installments, such that the option would be fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occurred first.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.